Trump’s Malaria Drug Hydroxychloroquine Fails Another Trial

The malaria treatment frequently lauded by U.S. President Trump as a game-changer in the battle against the novel coronavirus has again failed to show a benefit in patients hospitalized with COVID-19, based on a study released Thursday.

Trump’s Malaria Drug Hydroxychloroquine Fails Another Trial

While the research being featured in the New England Journal of Medication had certain limitations, doctors reported that using hydroxychloroquine neither lessened the need for sufferers requiring breathing assistance nor the risk of death.

Among sufferers given hydroxychloroquine, 32.3% ended up needing a ventilator or dying, compared with 14.9% of sufferers who were not given the drug.

However, doctors have been extra likely to give hydroxychloroquine to sicker sufferers, so researchers at New York-Presbyterian Hospital and Columbia University Irving Medical Heart adjusted the rates to account for that. They concluded that the drug might not have harm patients, but it clearly didn’t help.

Decades-old hydroxychloroquine, which is also used to treat lupus and rheumatoid arthritis, also showed no benefit when mixed with the antibiotic azithromycin, Schluger’s team reported.

In April, doctors at the U.S. Division of Veterans Affairs posted that hydroxychloroquine didn’t help COVID-19 sufferers and might pose a higher danger of death.

That analysis of medical records confirmed a death rate of 28% when the drug was given along with standard therapies, in comparison with 11% with standard care alone.